Law Firm Investigates Madrigal Pharmaceuticals Following Whistleblower Complaint and Stock Drop
· GlobeWire Daily Business Desk · Source: www.prnewswire.com

Original GlobeWire Daily editorial illustration — not an event photograph.
Law firm Kessler Topaz Meltzer & Check, LLP announced an investigation into potential federal securities law violations by Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) on behalf of investors who experienced financial losses. The announcement follows a public disclosure by Madrigal regarding a whistleblower complaint filed by its former Senior Vice President and Head of Clinical Development.
According to reports, investors can review official announcements and verify details directly through the law firm's official website or by contacting designated legal counsel.
Whistleblower Complaint and Disclosures
On November 3, 2026, Madrigal disclosed in a quarterly report that its former Senior Vice President and Head of Clinical Development filed a whistleblower complaint on October 9, 2026. The complaint alleges that the executive reported several issues to senior leadership regarding Rezdiffra, the company's approved drug:
- Suppression of adverse liver-injury data.
- Presentation of efficacy results that could not be reconciled with source data.
- Permitting an unblinded Board member to control the adjudication of clinical outcomes.
Market Impact and Shareholder Implications
Following the public disclosure of the whistleblower complaint, Madrigal's stock price dropped by over 8%. Investors who purchased or acquired Madrigal securities and incurred financial losses are reviewing their legal rights under federal securities laws. Legal representatives note that discussions carry no cost or obligation.
AI-assisted reporting; source claims are attributed and have not been independently verified.



